The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study.
 
Manali Kirtikumar Kamdar
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Genentech/Roche; Syncopation Life Sciences
Speakers' Bureau - Seagen
Research Funding - Novartis
 
Scott R. Solomon
No Relationships to Disclose
 
Jon Arnason
Honoraria - Bristol-Myers Squibb/Celgene/Juno
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene/Juno
 
Patrick B. Johnston
No Relationships to Disclose
 
Bertram Glaß
Employment - Helios Klinik Berlin-Buch GmbH
Honoraria - Abbvie (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Incyte (Inst); Miltenyi Biotec (Inst); Novartis (Inst); Roche (Inst); Sobi (Inst)
Consulting or Advisory Role - Abbvie (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Incyte (Inst); Miltenyi Biotec (Inst); Novartis (Inst); Roche (Inst); Sobi (Inst)
Research Funding - Roche (Inst)
Expert Testimony - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Abbvie (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Roche (Inst)
 
Veronika Bachanova
No Relationships to Disclose
 
Sami Ibrahimi
Stock and Other Ownership Interests - Karyopharm Therapeutics
Consulting or Advisory Role - Ipsen
 
Stephan Mielke
Leadership - SWECARNET: Founder/Leadership (Inst)
Speakers' Bureau - Celgene/Bristol-Myers Squibb (Inst); Janssen (Inst); Kite/Gilead (Inst); Novartis (Inst); Pfizer (Inst)
Expert Testimony - Kite/Gilead (Inst)
Travel, Accommodations, Expenses - Kite/Gilead (Inst)
Other Relationship - Immunicum/Mendes: Data safety monitoring board (Inst); Miltenyi: Data safety monitoring board (Inst)
 
Pim Mutsaers
Consulting or Advisory Role - GlaxoSmithKline
Other Relationship - AstraZeneca - grants
 
Francisco J. Hernandez-Ilizaliturri
Consulting or Advisory Role - Abbvie; BeiGene; Epizyme; Kite/Gilead; Morphosys; Novartis; Pharmacyclics; Seagen
 
Koji Izutsu
Honoraria - Abbvie; Abbvie; Allergan; AstraZeneca; Bayer; Bristol Myers Squibb; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Fujifilm; HUYA Bioscience International; Janssen; Janssen; Kyowa Kirin; Lilly; Meiji Seika Kaisha; Meiji Seika Kaisha; MSD; MSD; Mundipharma; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Pfizer; SymBio Pharmaceuticals; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; AstraZeneca; Bayer; Bristol Myers Squibb; Celgene; Genmab; Kyowa Kirin; Mitsubishi Tanabe Pharma; Nippon Shinyaku; Ono Pharmaceutical
Research Funding - Chugai Pharma; Eisai
 
Franck Morschhauser
Honoraria - Chugai/Roche; Roche/Genentech; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Genmab; Gilead Sciences; Modex therapeutics; Novartis; Roche/Genentech
 
Matthew Alexander Lunning
Consulting or Advisory Role - Abbvie; Acrotech Biopharma; ADC Therapeutics; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; crispr therapeutics; Daiichi Sankyo/Lilly; EUSA Pharma; Fate Therapeutics; Genentech; Genmab; Instil Bio; Ipsen; Kite, a Gilead company; Loxo; Miltenyi Biotec; MorphoSys; Novartis; Nurix; Pharmacyclics; Regeneron; Sanofi; Seagen; Takeda; TG Therapeutics
Research Funding - Celgene (Inst); curis (Inst)
 
Victor A. Chow
No Relationships to Disclose
 
Josu Santamaria
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Silvia Colicino
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Novartis
 
Ken Ogasawara
Employment - Bristol Myers Squibb; SpringWorks Therapeutics (I); Takeda (I)
Stock and Other Ownership Interests - Bristol Myers Squibb; Takeda (I)
 
Lara Stepan
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Amgen; Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Jeremy S. Abramson
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb/Celgene; Janssen; Kite, a Gilead company; Regeneron
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Alimera Sciences; AstraZeneca; BeiGene; Bluebird Bio; Bristol-Myers Squibb; C4 Therapeutics; Caribou Biosciences; Celgene; Cellectar; Century Therapeutics; EMD Serono; Epizyme; Genmab; Incyte; Interius Biotherapeutics; Janssen; Karyopharm Therapeutics; Kite, a Gilead company; Kymera; Lilly; MorphoSys; MorphoSys; MustangBio; Novartis; Ono Pharmaceutical; Roche/Genentech; Seagen; Takeda
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Cellectis (Inst); Merck (Inst); MustangBio (Inst); Regeneron (Inst); Seagen (Inst)